The purpose of this study was to investigate the pharmacokinetics of teicoplanin (TEIC) in patients undergoing open heart surgery. We also attemped to define the optimum TEIC therapy protocol for prevention of perioperative infection and for treatment of staphylococcal endocarditis such as that caused by methicillin-resistant Staphylococcus aureus (MRSA). Serum TEIC concentrations were measured in 14 patients divided into two groups of 7 patients each undergoing elective open heart surgery. Patients in group I received 400mg of TEIC and patients in group II received 800mg, both administered as a slow intravenous infusion over 20min immediately after induction of anesthesia. The peak serum level (mean±standard error) of TEIC was respectively 57±11 and 139±39μg/ml at 2min after administration and then the TEIC level decreased gradually to 26± 7 and 55±10μg/ml at 60min after administration. The serum level of TEIC decreased rapidly to 17±5 and 31±7μg/ml, respectively, at the start of extracorporeal circulation (ECC), and was 11±2 and 27±6μg/ml after 60min of ECC, 8±2 and 23±7μg/ml at 2min after the termination of ECC, 8±3 and 23±6μg/ml at 60min after the termination of ECC, and 7±2 and 22±5μg/ml on admission to ICU. No side effects were seen during the study, such as red neck syndrome, renal dysfunction, hearing disorders, or postoperative infection. Our results suggested that the optimum dose of TEIC for prevention of perioperative infection was around 400mg, providing levels in excess of the MIC for most pathogens that have been found to cause infection following open heart surgery, including MRSA. In addition, a dose of 800mg was needed to keep trough levels above 20μg/ml for treatment of staphylococcal endocarditis. It was also suggested that half of the initial dose should be administered on admission to ICU and also at the start of ECC if the operation is going to last longer than 7h on the basis of the concentration-time curve.

The effect of octylphthalide (OP) bathing was compared with placebo bathing on patients with rheumatoid arthritis (RA).
A liquid containing octylphthalide was dissolved in water of 40°C at a concentration of 10ppm. A liquid which has quite similar appearance and perfume to the above was used as a placebo. Double blind controlled study tests were performed.
Twenty patients (10 for OP bathing and 10 for placebo bathing) were tested by single bathing, 33 other patients (16 patients for OP bathing and 17 for placebo bathing), by serial bathing for 30 days (once a day).
After a single bathing, while grip strengths, tender joints scores, and 20m walking time improved significantly in the OP bathing group, only tender joint scores and 20m walking time improved significantly in the placebo bathing group.
After serial bathing for 30 days, tender joint scores improved significantly in the OP bathing group, but no improvement was observed in the placebo bathing group. The above results suggest that OP bathing may be beneficial for RA patients, but further study may be needed.